APOE ε4 is the largest genetic risk factor — but genetics is not destiny. Knowing enables acting early.
helixXY analyzes your APOE genotype (ε2/ε3/ε4) and variants in TREM2, BIN1, CLU, PICALM and SORL1 — the main susceptibility loci for late-onset Alzheimer's.
Alzheimer's Disease is a progressive neurodegeneration with cerebral beta-amyloid and Tau deposits. Although heterogeneous, its genetic architecture is well known: late-onset form (>65 years) has ~60–80% heritability, dominated by the APOE gene and modulated by dozens of other loci.
The APOE ε4 allele is the largest genetic risk factor: homozygotes can have up to 12× risk. But the opposite is also true — the ε2 allele is protective, reducing risk by ~50%.
Great news: ~40% of dementia risk is modifiable. The Lancet Commission identified 12 avoidable risk factors. Knowing genetics enables prioritizing prevention where it most benefits.
~5% of the population carries the ε2 allele, which reduces risk by ~50%. Identifying who's ε2/ε2 homozygous is as valuable as identifying ε4/ε4.
FINGER trial proved: multidomain intervention (diet, exercise, cognitive training, vascular control) reduces cognitive decline even in APOE ε4 carriers.
Use your file from 23andMe, Genera, AncestryDNA, etc. Within 15 minutes of upload, your report is ready.
Cognitive engagement, continuous learning, and social activity are among the 12 modifiable factors that reduce dementia risk by up to 40%.
Photo from Pexels
IGAP and PGC-ALZ meta-analyses with over 500,000 individuals mapped Alzheimer's genetic atlas. APOE accounts for ~25% of heritability — a giant effect for a single region.
Photo from Pexels
APOE dominates, but TREM2, BIN1, CLU, PICALM and SORL1 modulate critical pathways: brain lipidome, innate immunity, endocytosis, and APP processing.
Apolipoprotein E — the largest known genetic risk factor for late-onset Alzheimer's. The ε4 allele raises risk 3× (ε3/ε4 heterozygotes) and up to 12× (ε4/ε4 homozygotes). Acts in cerebral lipid transport and beta-amyloid clearance. ε2 is protective; ε3 is the neutral common allele.
Triggering Receptor Expressed on Myeloid Cells 2 — essential receptor for microglial function. Rare variants (R47H, R62H) reduce microglia's ability to degrade amyloid plaques. Recent doctrine: Alzheimer's is also a disease of cerebral innate immunity.
Bridging Integrator 1 — second largest non-APOE locus for Alzheimer's. Involved in endocytosis, Tau protein trafficking, and synaptic function. BIN1 variants alter Tau processing and modulate disease progression.
Clusterin (Apolipoprotein J) — molecular chaperone involved in beta-amyloid transport and protection from oxidative stress. CLU variants were the first non-APOE locus discovered by GWAS in 2009. Acts coordinately with APOE in amyloid clearance.
Phosphatidylinositol Binding Clathrin Assembly Protein — regulator of clathrin-mediated endocytosis. Influences APP (amyloid precursor protein) internalization and processing, and beta-amyloid clearance across the blood-brain barrier.
Sortilin-Related Receptor 1 — intracellular sorting protein that regulates APP trafficking and processing. Rare SORL1 variants can cause early-onset Alzheimer's; common variants moderately raise late-onset risk. Convergence between common and rare genetic factors.
Additional loci also analyzed: The report also includes variants in ABCA7, CR1, MS4A6A, EPHA1, CD33, CD2AP, INPP5D, PLCG2 and 70+ other loci identified by the International Genomics of Alzheimer's Project (IGAP).
Photo from Pexels
Alzheimer's brain changes begin 20–30 years before symptoms. Discovering risk at 40 or 50 gives real time to act: aerobic exercise, MIND diet, blood pressure and glucose control, sleep quality, social and cognitive engagement.
The new generation of anti-amyloid medications (lecanemab, donanemab) works better the earlier started. Identifying APOE ε4 early opens the door to earlier diagnosis of brain changes — and treatment at the ideal moment.
Unambiguous identification of your APOE genotype (ε2/ε3/ε4), with homozygosity and heterozygosity determination — the most relevant genetic information for Alzheimer's.
We combine APOE + TREM2 + 70+ additional loci into a Polygenic Risk Score (AD-PRS) validated in IGAP and UK Biobank cohorts.
Each finding comes with literature reference, risk percentages at different ages, and contextualization for your ancestry.
The Lancet Commission's 12 modifiable factors prioritized for your profile — BP control, exercise, MIND diet, sleep, hearing, cognitive engagement.
As new loci and prevention/treatment trials (lecanemab, donanemab) advance, your report is automatically revised.
Your data is processed with AES-256 encryption in zero-knowledge architecture. Full GDPR compliance.
The difference between normal aging forgetfulness and Alzheimer's is in the progressive pattern and interference with daily life.
Forgetting recently learned information, important dates, events. Needing to repeat the same questions. Cardinal sign of Alzheimer's.
Problems preparing a known recipe, driving to a familiar place, managing accounts, forgetting rules of favorite games.
Losing track of dates, seasons, or passage of time. Forgetting where they are or how they arrived somewhere.
Difficulty following conversations, stopping mid-sentence not knowing how to continue, substituting correct words for incorrect ones.
Confusion, suspicion, depression, anxiety. People become more irritable or anxious in situations outside their comfort zone.
Putting things in unusual places (remote in the fridge, keys in the freezer) and being unable to retrace steps to find them.
Our analysis integrates data from the International Genomics of Alzheimer's Project (IGAP), Psychiatric Genomics Consortium (PGC-ALZ), UK Biobank, and the Lancet Commission on Dementia 2020 — aligned with Alzheimer's Association and Academy of Neurology guidelines.
Important medical notice: APOE ε4 is a risk factor, not a diagnosis. Many carriers never develop Alzheimer's, and many non-carriers do. Diagnosis requires clinical neurological evaluation, neuropsychological tests, imaging (MRI, PET), and CSF biomarkers by a specialist physician. Always consult a neurologist or geriatrician.
Upload your genetic file and receive your Alzheimer's risk report in under 15 minutes.
No spam. Cancel anytime.